TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07662213: A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Oral Semaglutide in Adults With Type 2 Diabetes Mellitus (Eluminate-2)

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 1200 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$11,550,280

Rescue Site Savings

+$7,637,328

Unlock Full NCT07662213 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07662213 Rescue Dossier →